XEQUEL

Welcome to the Brand page for “XEQUEL”, which is offered here for Pharmaceutical and biological preparations utilizing act1 peptide to restore connexin43 protein junction integrity in cells, ophthalmic eye drops useful in treating corneal injuries or ocular injury due to chemical agents, dermatological topical formulations useful in treating cutaneous radiation injuries, cutaneous scarring, and thermal burns, and inhalation solutions useful in treating acute lung injuries;sequel;biopharmaceutical research and development services utilizing act1 peptide to restore connexin43 protein junction integrity in cells, in the fields of dermatology, ophthalmology, and pulmonology;.

Its status is currently believed to be active. Its class is unavailable. “XEQUEL” is believed to be currently owned by “Xequel Bio, Inc.”